Achieve Life Sciences Prepares for Major Healthcare Conference
SEATTLE and VANCOUVER, British Columbia – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a leading specialty pharmaceutical company, focuses on the innovative development of cytisinicline to aid in smoking cessation. The firm proudly announces its participation in the Barclays 27th Annual Global Healthcare Conference, scheduled for March 11-13. This prestigious event will take place in Miami, showcasing significant advancements in healthcare.
Insights on the Upcoming Presentation
Rick Stewart, the Chief Executive Officer of Achieve Life Sciences, is set to take the stage on March 12 at 11:30 AM EDT. This presentation is vital as it highlights the company's commitment to combating nicotine dependence through research and development efforts. A live webcast of the presentation will enable global reach, allowing investors and stakeholders to participate in this crucial discussion.
An Invitation to Engage
To dive deeper into the company's strategy and updates, attendees are encouraged to visit the Investor Relations section of the Achieve Life Sciences website. This resource will offer access to additional insights and company news that is pivotal for understanding the landscape of nicotine dependence treatment.
Transforming Nicotine Dependence Treatment
Achieve Life Sciences is dedicated to addressing the global smoking health crisis through the development and commercialization of cytisinicline. This innovative treatment targets the epidemic of nicotine dependence, which has serious implications for public health. With two completed Phase 3 studies and a Phase 2 study focused on vaping cessation, the company is making significant strides toward fulfilling its mission.
Ongoing Studies and Regulatory Plans
The company has achieved impressive milestones in its research, including the successful enrollment of an open-label safety study for cytisinicline, further indicating the potential safety and effectiveness of this treatment. Plans are underway to submit a new drug application in the second quarter of the following year, a step that could lead to regulatory approval.
Understanding Cytisinicline
Cytisinicline is a natural alkaloid recognized for its effectiveness in aiding those struggling with nicotine addiction. The compound demonstrates a high binding affinity to the nicotinic acetylcholine receptor in the brain, playing a key role in mitigating cravings associated with smoking and vaping. The alarming number of adults suffering from tobacco-related illnesses, coupled with the rise of e-cigarette use, highlights the urgent need for effective cessation solutions.
The Importance of Addressing Nicotine Addiction
With millions of adults using combustible cigarettes and e-cigarettes, smoking remains the leading cause of preventable disease. It's responsible for eight million deaths globally each year. Achieve Life Sciences recognizes that conventional treatments for nicotine addiction often fall short, thus focusing on the development of cytisinicline, which has received Breakthrough Therapy designation from the FDA, emphasizing its importance in addressing these critical health issues.
A Future Filled with Hope
As Achieve Life Sciences prepares for its presentation at the Barclays Global Healthcare Conference, the company remains committed to advancing the development of cytisinicline as a groundbreaking treatment option. By engaging with stakeholders during this key event, Achieve aims to emphasize its vision of effectively treating nicotine dependence while fostering a healthier future for individuals currently affected by tobacco use.
Frequently Asked Questions
What is Achieve Life Sciences focused on?
Achieve Life Sciences focuses on developing cytisinicline to treat nicotine dependence and smoking cessation.
When will the Barclays Global Healthcare Conference take place?
The conference will occur from March 11-13 in Miami, Florida.
Who will present on behalf of Achieve Life Sciences?
Rick Stewart, the Chief Executive Officer, will be presenting at the conference.
What are the ongoing studies for cytisinicline?
Achieve Life Sciences has completed two Phase 3 studies and is currently enrolling participants in a safety study.
How many adults smoke cigarettes worldwide?
Approximately 29 million adults smoke combustible cigarettes, contributing to significant health risks globally.
